

Informazioni personali

Nome/cognome
Gisella Vischini

Nazionalità
Italia

Esperienze lavorative

Dal 1/4/2026 ad oggi con deliberazione n 291 del 31/03/2021 conferimento incarico quinquennale di Direttore di Unità Operativa Complessa Nefrologia e Dialisi (Hub e spoke)

Dal 1/7/2020 al 31/03/2026:

Nefrologo UOC Nefrologia dialisi e trapianto presso Policlinico Sant'Orsola IRCCS Bologna.

Giugno 2012- Maggio 2020:

Nefrologo divisione di Nefrologia e Dialisi Fondazione Policlinico A. Gemelli. Contratto a tempo indeterminato dal 2014

Marzo-maggio 2012

Direttore del centro dialisi NephroCare a Cassino (FR).

2010-2011

Nefrologo con contratto a termine determinato presso Nefrologia e Dialisi dell'ospedale Civitanova Marche, Macerata

2009-2010

Collaborazione medica con AIL (Associazione italiana per linfoma e leucemia) Fondazione a Roma

2009-2010

Financial grant for scientific research (entitled: Valutazione in vitro della clearance di piperacillina tazobactam e dell'infusione continua tramite sacche di reinfusione in corso di CRRT come metodo ottimale per mantenere la concentrazione dell'antibiotico al di sopra della concentrazione minima inibente) supported by Fresenius Medical Care in Nephrology and Dialysis Unit of San Eugenio Hospital, Rome-Italy.

Istruzione

Marzo 2017- Marzo 2018. Master II livello Renal Pathology, Università degli Studi di Milano ()

2017 Dottorato di Ricerca XXIX Ciclo in SCIENZE DELLA NUTRIZIONE, DEL METABOLISMO, DELL'INVECCHIAMENTO E DELLE PATOLOGIE DI GENERE, AA 2014-2017. Università Cattolica del Sacro Cuore, Roma

1-3-2016 \ 15-2-2017 Fellowship in patologia renale all'Università di Vanderbilt, Nashville (TN) sotto Dr Agnes Fogo direzione.

2009 Specializzazione in Nefrologia presso l'Università Tor Vergata di Roma (classe 50 cum laude)

2004 Laurea in medicina e chirurgia presso l'Università Tor Vergata di Roma (classe 110 cum laude)

1998 Diploma di maturità a Roma-Italia

Competenze personali

Insufficienza Renale Acuta- gestione clinica, extracorporea ed accessi femorali per emodialisi
Dialisi peritoneale
Patologia renale- gestione glomerulonefriti. Istopatologia renale (reni nativi e trapianto)
Gestione del paziente renale (IRC ed ESRD)

Competenze sociali

buona capacità di adattarsi agli ambienti multiculturali

Abilità e competenze informatiche

buon comando di strumenti di Microsoft Office TM (Word TM, Excel TM e PowerPoint TM) e iOS.

Pubblicazioni

1. Vischini G, Caissutti S, Vetrano D, Donini S, Mastromauro P, Chiocchini AL, Vella A, Magnoni G, Capelli I, Piccoli GB, La Manna G. Low protein diet with personalized support in advanced chronic kidney disease: association with disease progression, dialysis delay and mortality. *Clin Kidney J.* 2025 Nov 7;19(1):sfaf341. doi: 10.1093/ckj/sfaf341. PMID: 41608155; PMCID: PMC12836100.
2. Cazzaniga G, Carbone M, Barretta R, Casati G, Vatrano S, Gambaro G, Vischini G, Capelli I, Mignani R, Pasquinelli G, Pieruzzi F, Caroti L, Dervishi E, Allinovi M, Novelli L, Pisani A, Eccher A, Pagni F, L'Imperio V. Zebra bodies recognition by artificial intelligence (ZEBRA): a computational tool for Fabry nephropathy. *Sci Rep.* 2026 Jan 12;16(1):5072. doi: 10.1038/s41598-026-35466-w. PMID: 41526641; PMCID: PMC12876834.
3. Grimaldi A, Auletta A, Ciurli F, Aiello V, Vischini G, Fabbriozio B, Becherucci F, Pasquinelli G, La Manna G, Capelli I, Mignani R. Coexistence of Alport Syndrome and Fabry Disease in a Female with R112H Variant: Early Progression of Fabry Nephropathy. *Int J Mol Sci.* 2025 Dec 26;27(1):269. doi: 10.3390/ijms27010269. PMID: 41516147; PMCID: PMC12786021.
4. Vischini G, Tacchetti P, Pavan L, Barbuto S, Vetrano D, Campus A, Grandinetti V, Massarotti L, Zatta I, Mancuso K, Petrucci MT, Zambello R, La Manna G. Belamaf: is renal toxicity an overlooked side effect? *Blood Adv.* 2026 Mar 10;10(5):1811-1812. doi: 10.1182/bloodadvances.2025018309. PMID: 41364882; PMCID: PMC13002534.
5. Campus A, Vischini G, Vetrano D, Di Nunzio M, Croci Chiocchini AL, Stalteri L, Grandinetti V, La Manna G. Renal Complications in Solid Tumor Patients Referred to an Onconeurology Clinic: A Three-Year Italian Experience. *G Ital Nefrol.* 2025 Oct 24;42(5):2025-vol5. doi: 10.69097/42-05-2025-03. PMID: 41184186.
6. Talarico M, Vischini G, Barbato S, Restuccia R, Masci S, Sacchetti I, Manzato E, Ghibellini S, Puppi M, Iezza M, Rizzello I, Pantani L, Tacchetti P, Borsi E, Solli V, Terragna C, Agostinelli C, La Manna G, Cavo M, Zamagni E, Mancuso K. Case Report: Uncommon co-occurrence of different renal histopathological entities in a patient with multiple myeloma and

- lymphoplasmacytic lymphoma. *Front Oncol.* 2025 Oct 7;15:1672690. doi: 10.3389/fonc.2025.1672690. PMID: 41127021; PMCID: PMC12537418.
7. Mignani R, Berti GM, Vischini G, Di Costanzo R, Ciurli F, Vetrano D, Biagini E, Serratore S, Fabbrizio B, Pasquinelli G, La Manna G, Capelli I. Functional and histopathologic correlation in the fabry nephropathy with N215S genotype. *Orphanet J Rare Dis.* 2025 Sep 2;20(1):468. doi: 10.1186/s13023-025-03994-9. PMID: 40898253; PMCID: PMC12403288.
 8. Caissutti S, Vischini G, Petroni ML, Collini S, Chiocchini ALC, La Manna G. Ketogenic diet as rescue therapy to access transplantation in obese and advanced stage IV-CKD patients: a case report and literature review. *J Nephrol.* 2025 Jul;38(6):1743-1750. doi: 10.1007/s40620-025-02335-0. Epub 2025 Jul 4. PMID: 40613980.
 9. Capelli I, Martano L, Berti GM, Vischini G, Lerario S, Donadio V, Incensi A, Aiello V, Ciurli F, Fabbrizio B, Chilotti S, Mignani R, Pasquinelli G, La Manna G. The Role of Kidney Biopsy in Fabry Disease. *Biomedicines.* 2025 Mar 21;13(4):767. doi: 10.3390/biomedicines13040767. PMID: 40299366; PMCID: PMC12024948.
 10. Mignani R, Berti GM, Vischini G, Di Costanzo R, Ciurli F, Fabbrizio B, Pasquinelli G, La Manna G, Capelli I. The Fabry Nephropathy in Patients with N215S Variant. *Nephron.* 2025;149(10):604-608. doi: 10.1159/000545611. Epub 2025 Apr 4. PMID: 40188808.
 11. Berti GM, Manaresi E, Vischini G, Provenzano M, Corradetti V, Giannella M, Bonazzetti C, Rinaldi M, Fabbrizio B, Ravaioli M, Gallinella G, La Manna G, Comai G. Exploring parvovirus B19 pathogenesis and therapy among kidney transplant recipients: case report and review of literature. *Lancet Infect Dis.* 2025 Jun;25(6):e360-e368. doi: 10.1016/S1473-3099(24)00560-7. Epub 2025 Mar 10. PMID: 40081401.
 12. Berti GM, Aiello V, Vischini G, Lerario S, Ciurli F, Santostefano M, Donadio V, Biagini E, Fresina M, Fabbrizio B, Montanari F, Turchetti D, Pasquinelli G, Mignani R, La Manna G, Capelli I. The importance of a multidisciplinary approach in two tricky cases: the perfect match for Fabry disease. *BMC Nephrol.* 2025 Feb 13;26(1):77. doi: 10.1186/s12882-025-04009-2. PMID: 39948544; PMCID: PMC11827196.
 13. Lafayette R, Tumlin J, Fenoglio R, Kaufeld J, Pérez Valdivia MÁ, Wu MS, Susan Huang SH, Alamartine E, Kim SG, Yee M, Kateifides A, Rice K, Garlo

- K, Barratt J; SANCTUARY Study Investigators. Efficacy and Safety of Ravulizumab in IgA Nephropathy: A Phase 2 Randomized Double-Blind Placebo-Controlled Trial. *J Am Soc Nephrol*. 2025 Apr 1;36(4):645-656. doi: 10.1681/ASN.0000000534. Epub 2024 Oct 25. PMID: 39455063; PMCID: PMC11975245.
14. Andrulli S, Gigante A, Rossini M, D'Angio' P, Vischini G, Luchetta F, Aucella F, Valsecchi G, Infante B, Vario MG, Giannese D, Granata A, Moggia E, Gembillo G, Cianci R, Bonomini M, Manenti F, Lazzarin R, Renzo BD, Zanchelli F, Garozzo M, Manes M, Battaglia Y, Sciri R, Fabritiis M, Quaglia M, Cavoli GL, Gintoli E, Conte MM, Borzumati M, Benozzi L, Pasquariello G, Andrulli G, Leoni M, Seminara G, Corbani V, Sabiu G, Maggio AD, Pollastro RM, Gesualdo L; ITA-KID-BIOPSY Group. How histopathological diagnosis interacts with kidney ultrasound parameters and glomerular filtration rate. *Intern Emerg Med*. 2024 Nov;19(8):2121-2132. doi: 10.1007/s11739-024-03711-7. Epub 2024 Sep 13. PMID: 39269540; PMCID: PMC11582157.
15. Maritati F, Corradetti V, Bini C, Provenzano M, Cuna V, Busutti M, Tondolo F, Zappulo F, Vischini G, Iacovella F, Abenavoli C, Borelli G, Demetri M, Fabbrizio B, Radi G, Ravaioli M, Mele C, La Manna G, Comai G. "Eculizumab First" in the Management of Posttransplant Thrombotic Microangiopathy. *Kidney Int Rep*. 2024 Jan 10;9(4):982-993. doi: 10.1016/j.ekir.2024.01.013. PMID: 38765562; PMCID: PMC11101752.
16. Aiello V, Ciurli F, Conti A, Cristalli CP, Lerario S, Montanari F, Sciascia N, Vischini G, Fabbrizio B, Di Costanzo R, Olivucci G, Pietra A, Lopez A, Zambianchi L, La Manna G, Capelli I. DNAJB11 Mutation in ADPKD Patients: Clinical Characteristics in a Monocentric Cohort. *Genes (Basel)*. 2023 Dec 19;15(1):3. doi: 10.3390/genes15010003. PMID: 38275584; PMCID: PMC10815778.
17. Przygocka A, Berti GM, Campus A, Tondolo F, Vischini G, Fabbrizio B, La Manna G, Baraldi O. Rituximab as possible therapy in TNF inhibitor-induced IgA vasculitis with severe renal involvement. *BMC Nephrol*. 2023 Dec 20;24(1):381. doi: 10.1186/s12882-023-03439-0. PMID: 38124070; PMCID: PMC10731765.
18. Vischini G, Speciale S, Przygocka A, Martano L, La Manna G, Baraldi O. Lessons for the clinical nephrologist: acute kidney injury during therapy with

- apixaban. *J Nephrol.* 2024 Mar;37(2):511-513. doi: 10.1007/s40620-023-01781-y. Epub 2023 Dec 6. PMID: 38055150; PMCID: PMC11043096.
19. Vasuri F, Lisi AP, Ciavarella C, Degiovanni A, Fabbrizio B, Valente S, Vischini G, La Manna G, D'Errico A, Pasquinelli G. Caveolin-1 in situ expression in glomerular and peritubular capillaries as a marker of ultrastructural progression and severity of renal thrombotic microangiopathy. *J Nephrol.* 2023 Nov;36(8):2327-2333. doi: 10.1007/s40620-023-01645-5. Epub 2023 Jul 22. PMID: 37480399.
20. Donati G, Przygocka A, Zappulo F, Vischini G, Valente S, La Manna G. Acute myeloma kidney and SARS-COV2 infection with dialysis need: never say never - a case report. *BMC Nephrol.* 2023 Jul 6;24(1):204. doi: 10.1186/s12882-023-03237-8. Erratum in: *BMC Nephrol.* 2023 Sep 8;24(1):264. doi: 10.1186/s12882-023-03301-3. PMID: 37415110; PMCID: PMC10324208.
21. Calìo A, Barreca A, Marletta S, Achenza MIS, Alessi M, Angelico R, Apicella L, Argiolas D, Bossini N, Carrano R, Carriero C, Castellano G, Comai G, Di Bella C, D'Ignoto F, Gallico A, Gastaldon F, Merlotti G, Paloschi V, Panarese A, Parodi A, Perna F, Picciotto D, Regalia A, Rossini M, Russo E, Salerno MP, Toti L, Tulissi P, Vischini G, Zaza G, Eccher A. Histology for nephrology, from pre-implantation to post-transplant kidney biopsy. Lesson learned from ReBIrth (Renal Biopsy for Kidney Transplantation Therapy). *Pathologica.* 2023 Jun 14. doi: 10.32074/1591-951X-858. Epub ahead of print. PMID: 37314869.
22. De Giglio A, Grandinetti V, Aprile M, Borelli G, Campus A, Croci Chiocchini AL, Busutti M, Vischini G, Di Federico A, Sperandi F, Melotti B, Ardizzoni A, La Manna G, Gelsomino F. Patterns of renal toxicity from the combination of pemetrexed and pembrolizumab for advanced nonsquamous non-small-cell lung cancer (NSCLC): A single-center experience. *Lung Cancer.* 2022 Dec;174:91-96. doi: 10.1016/j.lungcan.2022.10.007. Epub 2022 Nov 2. PMID: 36356493.
23. Donati G, Abenavoli C, Vischini G, Cenacchi G, Costa R, Pasquinelli G, Ferracin M, Laprovitera N, Comai G, Monti G, Giostra F, La Manna G. Sick Cell Trait and SARS-CoV-2-Induced Rhabdomyolysis: A Case Report. *Am J Case Rep.* 2022 Feb 23;23:e934220. doi: 10.12659/AJCR.934220. PMID: 35194011; PMCID: PMC8884150.

24. Papalia G, Barbuto S, Campus A, Vischini G. Double glomerulopathies or two-faced janus? A challenging case in the COVID-19 era. *J Nephrol*. 2022 Jun 6;1–4. doi: 10.1007/s40620-022-01351-8. Epub ahead of print. PMID: 35666373; PMCID: PMC9169020.
25. L'Imperio V, Vischini G, Ferraro M, Pagni F. Response to: 'Correspondence on 'Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications'' by Hakroush and Tampe. *Ann Rheum Dis*. 2021 Feb 5:annrheumdis-2021-219988. doi: 10.1136/annrheumdis-2021-219988. Epub ahead of print. PMID: 33547064.
26. Petricca L, Gigante MR, Paglionico A, Costanzi S, Vischini G, Di Mario C, Varriano V, Tanti G, Tolusso B, Alivernini S, Grandaliano G, Ferraccioli G, Gremese E. Rituximab Followed by Belimumab Controls Severe Lupus Nephritis and Bullous Pemphigoid in Systemic Lupus Erythematosus Refractory to Several Combination Therapies. *Front Med (Lausanne)*. 2020 Oct 28;7:553075. doi: 10.3389/fmed.2020.553075. PMID: 33195302; PMCID: PMC7657367.
27. L'Imperio V, Vischini G, Pagni F, Ferraro PM. Bowman's capsule rupture on renal biopsy improves the outcome prediction of ANCA-associated glomerulonephritis classifications. *Ann Rheum Dis*. 2022 Jun;81(6):e95. doi: 10.1136/annrheumdis-2020-217979. Epub 2020 Jun 12. PMID: 32532749.
28. Andrulli S, Manenti L, Reggiani F, Pisani I, Giannese D, Vischini G, Valsecchi G, Godeas G, Gigliotti G, Esposito P, De Giovanni P, Murtas C, Casuscelli C, Caruso S, Rossini M, Andrulli G, Quaglia M, Aucella F, Buscaroli A, Rossi GM, Mattozzi F, Di Renzo B, Zanchelli F, Bruno F, Sciri R, Manes M, Torres DD, Garozzo M, Lazzarin R, Corbani V, Fontana F, Calatroni M, Incerti M, Bini C, Infante B, D'Angio' P, Di Martino M, Rigotti A, Gesualdo L. Isolated C3 hypocomplementemia as an early predictor of chronic kidney disease in lupus nephritis. *Front Immunol*. 2025 Sep 12;16:1655825. doi: 10.3389/fimmu.2025.1655825. PMID: 41019087; PMCID: PMC12464744.
29. Vischini G, D'Alonzo S, Grandaliano G, D'Ascenzo FM. SARS-CoV-2 in the peritoneal waste in a patient treated with peritoneal dialysis. *Kidney Int*. 2020 Jul;98(1):237-238. doi: 10.1016/j.kint.2020.05.005. Epub 2020 May 12. PMID: 32413379; PMCID: PMC7217108.

30. Calvaruso L, Naticchia A, Ferraro PM, Vischini G, Costanzi S. Deterioration in Clinical Status Is Not Enough to Suspend Eculizumab: A Genetic Complement-Mediated Atypical Hemolytic Uremic Syndrome Case Report. *Case Rep Nephrol.* 2019 Jul 9;2019:9264824. doi: 10.1155/2019/9264824. PMID: 31360562; PMCID: PMC6652041.
31. Masola V, Bellin G, Vischini G, Dall'Olmo L, Granata S, Gambaro G, Lupo A, Onisto M, Zaza G. Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury. *Oncotarget.* 2018 Nov 16;9(90):36185-36201. doi: 10.18632/oncotarget.26324. PMID: 30546836; PMCID: PMC6281411
32. MAL DI-MSI Pilot Study Highlights Glomerular Deposits of Macrophage Migration Inhibitory Factor (MIF) as a Possible Indicator of Response to Therapy in Membranous Nephropathy. L'Imperio V, Smith A, Ajello E, Piga I, Stella M, Denti V, Tettamanti S, Sinico RA, Pieruzzi F, Garozzo M, Vischini G, Nebuloni M, Pagni F, Magni F. *Proteomics Clin Appl.* 2018 Oct 25:e1800019
33. A unique evolution of the kidney phenotype in a patient with autosomal recessive Alport syndrome. Vischini G, Kapp ME, Wheeler FC, Hopp L, Fogo AB. *Hum Pathol.* 2018 Mar 9. pii: S0046-8177(18)30076-5. doi: 10.1016/j.humpath.2018.02.024.
34. Defective activation of the MAPK/ERK pathway, leading to PARP1 and DNMT1 dysregulation, is a common defect in IgA nephropathy and Henoch-Schönlein. Milillo A, Molinaro C, Costanzi S, Vischini G, La Carpia F, La Greca F, Rigante D, Gambaro G, Gurrieri F, Sangiorgi E. *J Nephrol.* 2018 Mar 1. doi: 10.1007/s40620-018-0482-6.
35. Waldenstrom Macroglobulinemia. Kapp M.E., Vischini G., Fogo A.B. # Springer International Publishing AG 2017 H. Trachtman et al. (eds.), *Glomerulonephritis*, DOI 10.1007/978-3-319-27334-1_37-1
36. Inhibition of heparanase protects against chronic kidney dysfunction following ischemia/reperfusion injury. Valentina Masola, Gloria Bellin, Gisella Vischini, Luigi Dall'Olmo, Simona Granata, Giovanni Gambaro, Antonio Lupo, Maurizio Onisto, Gianluigi Zaza. *Oncotarget.* 2018 Nov 16; 9(90): 36185–3620
37. Heparanase: A Potential New Factor Involved in the Renal Epithelial Mesenchymal Transition (EMT) Induced by Ischemia/Reperfusion (I/R) Inju

- va ry. Masola V, Zaza G, Gambaro G, Onisto M, Bellin G, Vischini G, Khamaysi I, Hassan A, Hamoud S, Nativ O, Heyman SN, Lupo A, Vlodaysky I, Abassi Z. *PLoS One* 2016 Jul 28;11(7).
38. IgA nephropathy and infections. Rollino C, Vischini G, Coppo R. *J Nephrol.* 2016 Aug;29(4):463-8.
39. A SPRY2 mutation leading to MAPK/ERK pathway inhibition is associated with an autosomal dominant form of IgA nephropathy. Milillo A, La Carpia F, Costanzi S, D'Urbano V, Martini M, Lanuti P, Vischini G, Larocca LM, Marchisio M, Miscia S, Amoroso A, Gurrieri F, Sangiorgi E. *Eur J Hum Genet* 2015 Dec;23(12):1673-8
40. [Membranous glomerulonephritis secondary to allogeneic stem cell transplant: review of the literature]. Vischini G, Niscola P, Ferrannini M, Cupelli L, Tendas A, Scaramucci L, Giovannini M, Dentamaro T, de Fabritiis P, Palumbo R. *G Ital Nefrol.* 2012;29(4):394-403
41. Pregnancy desire unmasks a MYH9 syndrome in a kidney transplant woman. Vischini G, Farneti F, Niscola P, Stefoni A. *Saudi J Kidney Dis Transpl.* 2012 Jul;23(4):834-5.
42. Motor Disability in End-Stage Renal Failure: An Epidemiological Study on Italian Dialyzed Patients. Vischini G, Tendas A, Ferrannini M, Scaramucci L, Di Segni G, Giovannini M, Niscola P, Palumbo R. *Saudi J Kidney Dis Transpl* 2011;22(6):1236-123.
43. Increased plasma levels of tacrolimus after ingestion of green tea. Vischini G, Niscola P, Stefoni A, Farneti F. *Am J Kidney Dis.* 2011 Aug;58(2):329
44. Management of peritoneal dialysis within a home care program for haematological malignancies: concerns and perspectives illustrated by a case report. Gisella Vischini, Pasquale Niscola, Andrea Tendas, Marco Giovannini, Luca Cupelli, Gregorio Antonio Brunetti, Michele Ferrannini, Claudio Cartoni, Paolo de Fabritiis, Roberto Palumbo. *Indian Journal of Palliative Care* . Volume 17 / Issue 2 / May-August 2011
45. Opioid analgesics in patients with chronic renal failure: principles for use and current guidelines. Niscola P, Giovannini M, Vischini G, Scaramucci L, Ferrannini M, Tendas A, Cupelli L, Bondanini F, Di Daniele N, Palumbo R. *G Ital Nefrol.* 2011 May-Jun;28(3):269-77. Review. Italian.
46. Management of hematological malignancies in patients affected by renal failure. Niscola P, Vischini G, Tendas A, Scaramucci L, Giovannini M,

- Bondanini F, Romani C, Brunetti GA, Cartoni C, Cupelli L, Ferrannini M, Perrotti A, Del Poeta G, Palumbo R, de Fabritiis P. *Expert Rev Anticancer Ther.* 2011 Mar;11(3):415-32. Review.
47. Spontaneous bilateral kidney rupture during autologous stem cell transplantation in a patient affected by amyloidosis. Ferrannini M, Vischini G, De Angelis G, Giannakakis K, Arcese W. *NDT Plus.* 2011 Feb;4(1):56-9. doi: 10.1093/ndtplus/sfq168. Epub 2010 Oct 5
48. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Strippoli GF; Clinical Evaluation of the DOse of Erythropoietins Study Group (C.E. DOSE). *Trials.* 2010 Jun 9;11:70.
49. Fulminant thrombotic microangiopathy as a clinical presentation of an occult signet-ring cell carcinoma of the lung and misdiagnosed as idiopathic thrombotic thrombocytopenic purpura. Niscola P, Palmieri MB, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Palumbo R, Fratoni S. *Saudi Med J.* 2010 May;31(5):581
50. A very cheap renal replacement therapy in the intensive care unit: is it possible? Ferrannini M, Vischini G, Palumbo R, Di Daniele N. *Artif Organs.* 2010 Jun;34(6):523; author reply 523-4. Epub 2010 Apr 20.
51. Pain management in multiple myeloma. Niscola P, Scaramucci L, Romani C, Giovannini M, Tendas A, Brunetti G, Cartoni C, Palumbo R, Vischini G, Siniscalchi A, de Fabritiis P, Caravita T. *Expert Rev Anticancer Ther.* 2010 Mar;10(3):415-25.
52. The use of major analgesics in patients with renal dysfunction. Niscola P, Scaramucci L, Vischini G, Giovannini M, Ferrannini M, Massa P, Tatangelo P, Galletti M, Palumbo R. *Curr Drug Targets.* 2010 Jun;11(6):752-8. Review.
53. Rituximab in post allogeneic hematopoietic stem cell transplantation membranous nephropathy: a case report. Vischini G, Cudillo L, Ferrannini M, Di Daniele N, Cerretti R, Arcese W. *J Nephrol.* 2009 Jan-Feb;22(1):160-3.
54. Cystatin C: a promising misunderstood biomarker for the diagnosis of acute kidney injury. Ferrannini M, Vischini G, Di Daniele N. *Kidney Int.* 2008 Dec;74(12):1623

55. Rituximab in membranous nephropathy after haematopoietic stem cell transplantation. Ferrannini M, Vischini G, Di Daniele N. Nephrol Dial Transplant. 2008 Aug;23(8):2700-1;
56. Successful pregnancy in a uremic patient treated with single needle hemodialysis. Ferrannini M, Vischini G, Miani N, Staffolani E, Di Daniele N. Int J Artif Organs. 2007 Dec;30(12):1122-5.
57. Rheopheresis in vascular diseases. Ferrannini M, Vischini G, Staffolani E, Scaccia F, Miani N, Parravano MC, Louis MM, Splendiani G, Di Daniele N. Int J Artif Organs. 2007 Oct; 30(10):923-9

Viterbo 14/04/2026

VISCHINI
GISELLA
14.04.2026
19:28:26
UTC

